

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on September 4, 2007.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1623
Patent Application
Docket No. TPI-2900C3XC2
Serial No. 10/747,742

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Roy P. Issac
Art Unit : 1623
Applicants : Mark Tawa, Örn Almarsson, Julius F. Remenar
Serial No. : 10/747,742
Filed : December 29, 2003
Conf. No. : 2066
For : Pharmaceutical Propylene Glycol Solvate Compositions

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The applicants have not submitted a copy of the published U.S. application cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/mv

Attachment: Form PTO/SB/08 (1 page)